Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.

@article{Kotteas2008SafetyAE,
  title={Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.},
  author={Elias Alexandros Kotteas and Christina V Alamara and Maria Kiagia and Kosmas Pantazopoulos and Anastasios Boufas and Aspasia Provata and Adrianni Charpidou and Konstantinos Syrigos},
  journal={Anticancer research},
  year={2008},
  volume={28 1B},
  pages={529-33}
}
Zoledronic acid (Zometa, Novartis, Basel, Switzerland) is a new generation of bisphosphonates (BPs) with demonstrated clinical benefit in breast and prostate cancer patients with bone metastases. The safety and efficacy of intravenous zoledronic acid in lung cancer patients was assessed. In 86 patients with newly diagnosed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) and bone metastases, 4 mg of zoledronic acid was administered with rapid 15-minute intravenous infusion… CONTINUE READING